Equity Profile

PTGX

Protagonist Therapeutics, Inc.

Health CareBiotechnology$6.4B

Aug6Thu

Pre-Earnings Brief

UpcomingQ2-2026After Close5:00 PM EDT

Company Snapshot

Protagonist Therapeutics, Inc. is a biotechnology company focused on developing novel therapies for serious diseases....

Key Metrics to Watch

Earnings Per Share (EPS)

EPS is a key indicator of the company's profitability and financial health, which investors closely monitor.

N/A

Revenue Growth

Revenue growth reflects the company's ability to expand its market presence and commercialize its products.

N/A

1 more metrics, Wall Street expectations, options signals, track record, and call prep available with Pro.

PTGX Q2-2026 Earnings Preview

Context

Company Snapshot

Protagonist Therapeutics, Inc. is a biotechnology company focused on developing novel therapies for serious diseases. Operating in the health care sector, it aims to address unmet medical needs through innovative treatments, which is crucial as the demand for effective health solutions continues to grow.

Earnings Scorecard·Last 8Q

EPS Beat Streak

EPS Beat Rate

50%

Avg EPS Surprise

+397.37%

Avg Stock Reaction

-0.19%

Last Quarter Recap

In Q1 2026, Protagonist reported an EPS of $0.05, significantly beating expectations of a loss. However, revenue figures were not disclosed, leaving some uncertainty about overall performance.

Management Promises & Guidance

Focus on advancing clinical trials for key therapies.
Commitment to improving operational efficiencies.
Plans to enhance communication with investors regarding future developments.

Expectations

Wall Street Expectations

Overall, expectations for Protagonist's upcoming earnings are mixed, with uncertainty surrounding revenue and clinical trial outcomes. Investors are keen to see if the company can maintain its positive EPS trend.

Bull Case

If Protagonist continues to show strong EPS performance and provides positive updates on clinical trials, it could lead to increased investor confidence and stock price appreciation.

Bear Case

Conversely, if the company fails to meet expectations on revenue or provides negative updates on clinical trials, it could result in a significant decline in stock value.

Expectations

Two Questions That Matter

The print will turn on these two things.

What is the latest update on the clinical trials for key therapies?

This information is crucial as it can influence investor sentiment and the company's future revenue potential.

How does management plan to address revenue growth moving forward?

Understanding the strategy for revenue generation is essential for assessing the company's financial health and growth prospects.

Edge

What the Street Is Missing

Why consensus could be wrong

The Street may underestimate the potential impact of recent clinical trial successes, which could lead to stronger-than-expected revenue growth.

Supporting Evidence

The options market is pricing a 25.76% move, indicating significant expectations that may not align with historical performance.

Protagonist's recent EPS surprise of +107.67% suggests a trend of outperforming expectations that could continue.

Key Risk

If clinical trial results exceed expectations, it could significantly alter the market's perception of Protagonist's growth potential.

Edge

Thesis-Break Levels

Pre-commit to what would confirm each case.

The core thesis revolves around the company's ability to translate clinical trial success into commercial revenue.

Bull Confirmed If

A positive update on clinical trial results could confirm the bull case, indicating strong future revenue potential.

Bear Confirmed If

Any negative news regarding clinical trials or lack of revenue growth would confirm the bear case.

Pre-Earnings Positioning

Options Market

Implied Move

±25.76%

Historical Avg

±1.3%

Pricing rich

The options market is pricing in a substantial potential move, indicating that investors expect significant volatility around the earnings report.

Options are pricing ±18.2% while PTGX has averaged ±1.3% over the last 8 prints — setup is pricing rich.

Detail

ATM IV

0.5%

30d HV

39.0%

Calls (18K)P/C Ratio: 2.50Puts (100)

Edge

Insider Activity

Open-market trades by officers, directors, and 10%+ holders over the trailing 90 days.

Bought

$0.00

0 sh

0 insiders

Sold

$184,572.50

1,750 sh

1 insider

Net

$184,572.50

Net selling

Most Active Insiders· 1 open-market trade

Chief Financial OfficerAli Asif
$184,572.50

Preparation

Post-Print Playbook

Likely market behavior by outcome — not investment advice.

Beat & Raise

If Protagonist beats expectations and raises guidance, history suggests a potential stock increase of around 1.27%, confirming positive market sentiment.

In-Line / Cautious

If results are in line with expectations but management's commentary is cautious, the stock may experience muted movement as investors reassess their outlook.

Miss

Should the company miss expectations, history suggests a potential decline of approximately 0.80%, reflecting negative investor sentiment.

Earnings Track Record

Preparation

What to Listen For

Call Prep

1Updates on the progress of clinical trials for key therapies.
2Management's strategy for driving revenue growth.
3Any changes in operational efficiencies or cost management.
4Insights into market demand for Protagonist's products.
5Future guidance on EPS and revenue expectations.

See the full picture

AI-powered briefs, options data, and 20 quarters of history — everything you need before earnings.

No charge today · Auto-bills $8/mo after 7 days · Cancel anytime

More Earnings This Week

5 Reports

Danaos Corporation

Company Snapshot

Protagonist Therapeutics, Inc. is a biotechnology company focused on developing novel therapies for serious diseases....

Key Metrics to Watch

Earnings Per Share (EPS)

EPS is a key indicator of the company's profitability and financial health, which investors closely monitor.

N/A

Revenue Growth

Revenue growth reflects the company's ability to expand its market presence and commercialize its products.

N/A

1 more metrics, Wall Street expectations, options signals, track record, and call prep available with Pro.

PTGX Q2-2026 Earnings Preview

Context

Company Snapshot

Earnings Scorecard·Last 8Q

EPS Beat Streak

EPS Beat Rate

50%

Avg EPS Surprise

+397.37%

Avg Stock Reaction

-0.19%

Last Quarter Recap

In Q1 2026, Protagonist reported an EPS of $0.05, significantly beating expectations of a loss. However, revenue figures were not disclosed, leaving some uncertainty about overall performance.

Management Promises & Guidance

Focus on advancing clinical trials for key therapies.
Commitment to improving operational efficiencies.
Plans to enhance communication with investors regarding future developments.

Expectations

Wall Street Expectations

Bull Case

If Protagonist continues to show strong EPS performance and provides positive updates on clinical trials, it could lead to increased investor confidence and stock price appreciation.

Bear Case

Conversely, if the company fails to meet expectations on revenue or provides negative updates on clinical trials, it could result in a significant decline in stock value.

Expectations

Two Questions That Matter

The print will turn on these two things.

What is the latest update on the clinical trials for key therapies?

This information is crucial as it can influence investor sentiment and the company's future revenue potential.

How does management plan to address revenue growth moving forward?

Understanding the strategy for revenue generation is essential for assessing the company's financial health and growth prospects.

Edge

What the Street Is Missing

Why consensus could be wrong

The Street may underestimate the potential impact of recent clinical trial successes, which could lead to stronger-than-expected revenue growth.

Supporting Evidence

The options market is pricing a 25.76% move, indicating significant expectations that may not align with historical performance.

Protagonist's recent EPS surprise of +107.67% suggests a trend of outperforming expectations that could continue.

Key Risk

If clinical trial results exceed expectations, it could significantly alter the market's perception of Protagonist's growth potential.

Edge

Thesis-Break Levels

Pre-commit to what would confirm each case.

The core thesis revolves around the company's ability to translate clinical trial success into commercial revenue.

Bull Confirmed If

A positive update on clinical trial results could confirm the bull case, indicating strong future revenue potential.

Bear Confirmed If

Any negative news regarding clinical trials or lack of revenue growth would confirm the bear case.

Pre-Earnings Positioning

Options Market

Implied Move

±25.76%

Historical Avg

±1.3%

Pricing rich

The options market is pricing in a substantial potential move, indicating that investors expect significant volatility around the earnings report.

Options are pricing ±18.2% while PTGX has averaged ±1.3% over the last 8 prints — setup is pricing rich.

Detail

ATM IV

0.5%

30d HV

39.0%

Calls (18K)P/C Ratio: 2.50Puts (100)

Edge

Insider Activity

Open-market trades by officers, directors, and 10%+ holders over the trailing 90 days.

Bought

$0.00

0 sh

0 insiders

Sold

$184,572.50

1,750 sh

1 insider

Net

$184,572.50

Net selling

Most Active Insiders· 1 open-market trade

Chief Financial OfficerAli Asif
$184,572.50

Preparation

Post-Print Playbook

Likely market behavior by outcome — not investment advice.

Beat & Raise

If Protagonist beats expectations and raises guidance, history suggests a potential stock increase of around 1.27%, confirming positive market sentiment.

In-Line / Cautious

If results are in line with expectations but management's commentary is cautious, the stock may experience muted movement as investors reassess their outlook.

Miss

Should the company miss expectations, history suggests a potential decline of approximately 0.80%, reflecting negative investor sentiment.

Earnings Track Record

Preparation

What to Listen For

Call Prep

1Updates on the progress of clinical trials for key therapies.
2Management's strategy for driving revenue growth.
3Any changes in operational efficiencies or cost management.
4Insights into market demand for Protagonist's products.
5Future guidance on EPS and revenue expectations.